Skip to main content

Animations

MJFF Publications

5031 - 5040 of 8825 Results
Title
Year
  • Year
  • 2025
  • 2024
  • 2024
  • 2025
  • 2025
  • 2025
  • 2025
  • 2025
  • 2025
  • 2025
  • Summary Details
    OPEN
    Title: Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration
    Journal Name: eLife
    Publisher: eLife Sciences Publications, Ltd
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.7554/elife.98775.3
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Responsive Versus Continuous Deep Brain Stimulation for Speech in Essential Tremor: A Pilot Study
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.29865
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Long‐Read Sequencing Unravels the Complexity of Structural Variants in PRKN in Two Individuals with Early‐Onset Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.29914
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational Study
    Journal Name: JMIR Research Protocols
    Publisher: JMIR Publications Inc.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.2196/71955
    Best OA location URL: https://doi.org/10.2196/71955
    Citation Count: 0
  • Summary Details
    OPEN
    Title: High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mdc3.70367
    Citation Count: 3
  • Summary Details
    OPEN
    Title: α-Synuclein aggregates inhibit ESCRT-III through sequestration and collateral degradation
    Journal Name: Molecular Cell
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.molcel.2025.08.022
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Healthcare access and utilization of deep brain stimulation and supplementary care in black and white patients with Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2025.108057
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Genome-wide association study of REM sleep behavior disorder in Parkinson’s disease
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-025-01078-w
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1038/s41598-025-17658-y
    Citation Count: 0
  • Summary Details
    OPEN
    Title: A blood-based DNA damage signature in patients with Parkinson’s disease is associated with disease progression
    Journal Name: Nature Aging
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s43587-025-00926-x
    Citation Count: 5
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.